NASDAQ: NBP
NovaBridge Biosciences
$1.77
▼ -0.02 (-0.84%)as of 2026-09-03
1-year price · 252 sessions
Key stats
52-week range$1.77
$1.47$6.56
Today
- Open
- 1.79
- Day high
- 1.82
- Day low
- 1.77
- Prev close
- 1.79
- Volume
- 18K
Valuation
- Mkt cap
- $206M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.3
- P/S
- —
Dividend
- Yield
- —
- Per share
- —
Insider & institutional activity · SEC Form 4 / 13F
- ▼Insiders net selling -$12K over the last 3 months (0 open-market buys, 3 sales)
NovaBridge Biosciences (NBP) is a Healthcare company listed on NASDAQ. The stock is down 62% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4). Drillr has 1 published research article covering NBP.
NovaBridge Biosciences (NBP) financials & analyst ratings
Fundamentals (TTM)
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
Growth & returns
Revenue growth—
Revenue growth (fwd)—
EPS growth—
Return on equity-60.2%
Return on assets-53.4%
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NBP earnings date, history & EPS estimates
Next earnings
Nov 12, 2026in NaN days
EPS est $-0.08 · Revenue est —
Track record
Beat EPS in 3 of 9 quarters
Avg surprise -1056.0% (last 4 quarters)
Earnings history
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 20, 2026 | $-0.01 | $-0.22 | -2660.4% | — | — |
| Jun 29, 2026 | $-0.01 | $-0.11 | -1280.2% | — | — |
| Dec 18, 2025 | $-0.06 | $-0.25 | -316.7% | — | — |
| May 15, 2025 | $-0.06 | $-0.04 | +33.3% | — | — |
| Nov 14, 2024 | $-0.16 | $-0.25 | -56.3% | — | — |
| Aug 28, 2024 | $-0.51 | $-0.07 | +86.3% | — | — |
| Apr 30, 2024 | — | $-0.26 | — | $563995 | — |
| Mar 29, 2024 | $-0.10 | $0.02 | +116.2% | $164156 | — |
| Aug 17, 2023 | $-0.26 | $-0.28 | -7.2% | $1M | +41.2% |
| May 1, 2023 | — | $-0.56 | — | $20M | — |
| Nov 10, 2022 | — | $-0.41 | — | $4M | — |
| Aug 30, 2022 | $-0.16 | $-0.54 | -235.0% | $19M | +655.5% |
NBP insider trading activity (SEC Form 4)
Sentiment
0/100
Buys (3m)
0
Sells (3m)
3
Net (3m)
-$12.2K
Insider trades by month Buys Sells
Apr
May
Jun
Jul
Sep
Context3-month price +0.1%
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | Xu Cong Claireofficer: EVP, Clinical Development | Sell | 3,282 | $0.79 |
| Sep 1, 2026 | Xu Cong Claireofficer: EVP, Clinical Development | Option | 9,382 | — |
| Sep 1, 2026 | Xu Cong Claireofficer: EVP, Clinical Development | Option | 4,079 | — |
| Aug 25, 2026 | Lenz Robert A.director | Option | 7,486 | — |
| Aug 25, 2026 | Lenz Robert A.director | Option | 17,218 | — |
| Jul 10, 2026 | Hagler Mark Arnoldofficer: Chief Commercial Officer | Grant | 949,050 | $1.93 |
| Jul 10, 2026 | Lin Liwei Lorraineofficer: General Counsel | Grant | 254,780 | $1.93 |
| Jul 8, 2026 | Gupta Srishtidirector, officer: Chief Executive Officer | Grant | 3,000,000 | $2.01 |
| Jul 7, 2026 | Xu Cong Claireofficer: SVP, Clinical Development | Option | 5,405 | — |
| Jul 7, 2026 | Xu Cong Claireofficer: SVP, Clinical Development | Option | 12,432 | — |
| Jul 7, 2026 | Xu Cong Claireofficer: SVP, Clinical Development | Sell | 4,485 | $0.89 |
| Jun 30, 2026 | Fu Weidirector | Grant | 1,010,100 | — |
| Jun 30, 2026 | Fu Weidirector | Grant | 725,140 | $2.45 |
| Jun 30, 2026 | Fu Weidirector | Grant | 1,087,720 | $2.45 |
| Jun 24, 2026 | Cao Sean Wuxiongdirector, officer: Chief Bus. Development Officer | Grant | 181,290 | $1.53 |
Source: NBP SEC Form 4 filings, latest Sep 1, 2026. For informational purposes only — not investment advice.
See the full NBP insider & 13F page →Track NBP with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free